Atopic dermatitis in the COVID-19 era: Results from a web-based survey

Mantilla, Natalia Hernández; Sanclemente, Gloria; Tamayo, Liliana; López, Ángela Ortega; Seidel, Ángela; Chaparro, Daniela; Cortes, Andrés; Ortiz, Clara Inés; Arenas, Claudia Marcela; Meléndez, Esperanza; Amador, Julio Roberto; Colmenares, Lina María; Guzmán, Miguel; Torres, María Claudia; Tavera, Mariela; Torres, Mauricio; Vargas, Miriam; Novoa, Mónica; Rivera, Mónica; Vélez, Natalia; Mora, Oscar Yahevh Carrera; Medina, Oscar; Cárdenas, Paola Andrea

doi:10.1016/j.waojou.2021.100571

Cited by 10 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it appears that SARS-CoV-2 infection could exacerbate asthma symptoms, as it was shown by Ono et al [ 27 ]. Also, similar to asthma, AD symptoms worsened during COVID-19 [ 28 , 29 ]. Therefore, it could be suggested that although the allergic reaction may not be a predisposing factor for severe COVID-19, SARS-CoV-2 infection could exacerbate symptoms of an allergic reaction.…”

Section: Discussionmentioning

confidence: 99%

Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report

Klyucharova

Мартынова

Rizvanov³

et al. 2022

BioNanoSci.

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is characterized by wheals lasting more than 6 weeks and can be accompanied by angioedema. Treatment of the disease varies depending on the severity and includes first-line therapeutics such as non-sedative antihistamines. Second- and third-line treatments are used in severe and uncontrolled form of CSU. Environmental exposure and infections could trigger worsening symptoms. The goal of this study is to assess the effect of SARS-CoV-2 infection on CSU symptoms and the efficacy of the second- and third-line therapeutics for CSU management in COVID-19 patients. Our findings show that SARS-CoV-2 infection exacerbates CSU symptoms. Worsening of disease was indicated by decreased Urticaria Control Test (UCT) and increased Urticaria Activity Score (UAS). Treatment management was modified by switching to second- and third-line therapeutics; however, therapeutic control was achieved only in one patient. Our data demonstrates that SARS-CoV-2 infection contributes to the severity of CSU. Symptoms of CSU are more challenging to manage and require changes in treatment protocol, including second- and third-line therapeutics. We believe that severe inflammation triggered by SARS-CoV-2 infection contributes to the worsening of CSU symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report

Klyucharova

Мартынова

Rizvanov³

et al. 2022

BioNanoSci.

View full text Add to dashboard Cite

show abstract

“…In the time of COVID‐19 pandemic, the worldwide situation has an impact on appearing of relevant psychological adverse events such as depression or emotional fatigue. 34 This could impact on neuroendocrine modulation of skin inflammation and increase of itch. 35 Moreover, skin damage and worsen of the sickness can be related to changing of hygenic habits—increasing frequency of handwashing and using hand sanitizers.…”

Section: Methodsmentioning

confidence: 99%

“…Immunosuppressive effect of sunlight is limited because of less exposure. 34 Therefore, it is possible to expect intensification of skin diseases symptoms.…”

Section: Methodsmentioning

confidence: 99%

Body care activities and its consequences related to COVID‐19 pandemic

Mościcka

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Symptoms of illnesses related to COVID‐19 disease include also dermatological changes. Moreover, modification of cosmetic and hygenic habits are widely noted. Aim The aim of this paper is to review the literature focused on skin manifestations related to COVID‐19 disease. Materials and Methods In order to obtain information contained in this review article electronic databases, such as Google Scholar and PubMed, was searched. Only peer‐reviewed articles published in the past two years have been studied. Results and Discussion People have changed their cosmetics and hygenic habits, what has an impact on spreading COVID‐19 disease, as well as on the beauty industry and human health. Conclusion More emphasis should be placed on increasing knowledge about skin lesions, which may appear in course of the disease or are associated with changes in hygenic and cosmetics habits.

show abstract

“…In asthmatic children, environmental changes, altered medical practice and medication use, changes in transportation and travel patterns, school attendance and physical activity impacted asthma control during the pandemic 167 . A survey revealed that the majority of the AD patients experienced AD flares with mild worsening of the disease during the COVID-19 pandemic 168 . Dupilumab seems to be safe and crucial for a better outcome of COVID-19 and should be continued in AD patients during the COVID-19 pandemic 169 .…”

Section: Management Of Allergic Diseases During the Covid-19 Pandemicmentioning

confidence: 99%

Recent developments in the immunopathology of COVID-19

Gao

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of COVID-19 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4 and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) has been identified as an important cause of death of children with COVID-19. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. Atopic diseases, such as allergic asthma and rhinitis, have been shown to be associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, EAACI developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging SARS-CoV-2 variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID.

show abstract

Atopic dermatitis in the COVID-19 era: Results from a web-based survey

Cited by 10 publications

References 13 publications

Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report

Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report

Body care activities and its consequences related to COVID‐19 pandemic

Recent developments in the immunopathology of COVID-19

Contact Info

Product

Resources

About